Overview
The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients
Status:
Completed
Completed
Trial end date:
1997-05-01
1997-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the separate and combined efficacy of a standardized acupuncture regimen and amitriptyline on the relief of pain due to peripheral neuropathy and on the quality of life of HIV-infected patients. Both amitriptyline, an antidepressant, and acupuncture, a Chinese medical approach that uses needles to relieve pain, have been used successfully to reduce pain in some people. It is not known how effectively these approaches relieve or reduce pain in patients with peripheral neuropathy secondary to HIV infection.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)Treatments:
Amitriptyline
Amitriptyline, perphenazine drug combination
Criteria
Inclusion CriteriaConcurrent Medication:
Allowed:
- Antiretroviral therapy.
- Nonsystemic treatment of Kaposi's sarcoma.
- Maintenance with an existing regimen of analgesic medication or herbal treatment.
Concurrent Treatment: Required:
- Acupuncture.
Patients must have:
- HIV infection.
- Lower extremity peripheral neuropathy secondary to HIV infection.
- Pain for at least 2 weeks prior to study entry.
- Life expectancy of at least 6 months.
NOTE:
- Co-enrollment in other experimental protocols is permitted as long as dual
participation is allowed in those protocols.
Prior Medication:
Allowed:
- Antiretroviral therapy.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Known allergy to amitriptyline (not applicable for patients at sites using an
acupuncture only study design).
- EKG indicating malignant arrhythmia or cardiac conduction disturbances (not applicable
for patients at sites using an acupuncture only study design).
- Prison incarceration.
Concurrent Medication:
Excluded:
- Active treatment for an acute opportunistic infection or malignancy (nonsystemic
treatment of Kaposi's sarcoma is permitted).
- Other tricyclic antidepressants.
- MAO inhibitors.
Patients with the following prior conditions are excluded (not applicable for patients at
sites using an acupuncture only study design):
- History of cardiac disease.
- History of seizure disorder.
Prior Medication:
Excluded within 2 weeks prior to study entry:
- MAO inhibitors.
- Tricyclic antidepressants.